LYPS Intervention for HIV Prevention

(LYPS Trial)

This trial tests a new approach to prevent HIV using PrEP (pre-exposure prophylaxis), a medication that reduces the risk of contracting HIV. The study examines delivering PrEP through community health professionals in familiar settings, such as homes or mobile clinics, and incorporates a mobile app for support. This new method is called LYPS. Participants will receive either this new method or standard care with some app features. The trial suits individuals aged 13-24 who have had sex in the past year, do not have HIV, are willing to try PrEP, and have a smartphone. As an unphased trial, it offers a unique opportunity to explore innovative ways to access HIV prevention.

The trial information does not specify if you need to stop taking your current medications. However, if you have any significant health conditions or are participating in another trial with HIV medications, you may not be eligible.

Research has shown that the LYPS program, which includes PrEP (a medication to prevent HIV) and support through a mobile app, is under evaluation for safety and effectiveness. Although this specific study lacks detailed safety data, the FDA has already approved PrEP for preventing HIV, indicating the medication's general safety. Other studies have demonstrated that PrEP can be safe and effective when used properly. However, the LYPS program also incorporates a mobile app to help individuals adhere to their treatment plan, and the app's safety is still under evaluation. The LYPS program aims to make PrEP more accessible and support its use, which is already recognized as a safe method to prevent HIV.¹²³⁴⁵

Researchers are excited about the LYPS Intervention for HIV prevention because it offers a fresh approach to delivering PrEP (pre-exposure prophylaxis) care. Unlike traditional clinic-based models, LYPS takes PrEP directly to young people in their communities via a Community Health Professional, which could be a nurse or another healthcare expert. This is supplemented by a mobile app that provides real-time support between visits, making the intervention more accessible and personalized. This method could potentially enhance adherence to PrEP by meeting youth where they are, both physically and digitally, and providing continuous, tailored support.

Research has shown that PrEP (pre-exposure prophylaxis) effectively prevents HIV when taken as directed, reducing the risk of HIV from sex by about 99%. However, real-life effectiveness can vary due to challenges like accessing the medication and maintaining regular use. The LYPS program in this trial aims to address these challenges by providing PrEP through community health workers and supporting users with a mobile app to enhance adherence. This approach seeks to simplify consistent PrEP use, potentially increasing its effectiveness in preventing HIV. Participants in the LYPS Intervention arm will receive this community-based PrEP care, while those in the Enhanced Standard of Care (eSOC) Control Condition will receive usual clinic-based PrEP care, enhanced with limited access to the LYPS app.¹²⁶⁷⁸